Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole (TriSulfa-FPI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Sponsor:
Collaborator:
Junta de Andalucia
Information provided by (Responsible Party):
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
ClinicalTrials.gov Identifier:
NCT01777737
First received: January 25, 2013
Last updated: August 5, 2014
Last verified: August 2014

January 25, 2013
August 5, 2014
June 2013
September 2014   (final data collection date for primary outcome measure)
Evaluate the efficacy of oral cotrimoxazole versus placebo in idiopathic pulmonary fibrosis (IPF). [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Decline of the FVC ≥ 5% at 24 weeks and / or hospitalization for respiratory causes.
Same as current
Complete list of historical versions of study NCT01777737 on ClinicalTrials.gov Archive Site
  • Evaluate the safety of oral cotrimoxazole versus placebo in IPF. [ Time Frame: At 24 weeks ] [ Designated as safety issue: Yes ]
    • Time to progression
    • Any cause of hospitalization
    • Overall mortality
    • Incidence and severity of adverse events.
  • Evaluate the effect of cotrimoxazole on the natural history of Pneumocystis colonization in patients with IPF. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    - Molecular diagnosis of colonization by Pneumocystis jiroveci.
  • Identify the effects of cotrimoxazole systemic level of inflammatory activity in patients with IPF. [ Time Frame: At 24 weeks ] [ Designated as safety issue: Yes ]
    • Acute exacerbation of IPF
    • Scales of dyspnea
    • Reduction > 50% in the values of different proinflammatory cytokines
    • Reduction > 50% in the values of surfactant proteins.
    • Reduction > 50% in the values of chemokine CCL-18.
Same as current
Not Provided
Not Provided
 
Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis

First study to test the validity of the treatment of idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with cotrimoxazole.

Cotrimoxazole may improve the clinical course of the disease through eradication of Pneumocystis jiroveci colonization and other mechanisms as inhibiting the activation of alveolar macrophages and producing alterations in the surfactant system which favours the persistent activation of the inflammatory response and the development of pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that is clinically manifested by the appearance of effort dyspnea and impaired lung function.

The natural history of the disease is poorly understood and there is no clear consensus as to the most appropriate markers for predicting patient outcome.

This pilot controlled trial aims to test the efficacy and safety of cotrimoxazole in the treatment of IPF. This novel therapeutic strategy, with very encouraging preliminary data is based on its pathophysiological basis, primarily related to the elimination of Pneumocystis colonization. That elimination, could serve as a potent weapon for reducing morbidity and mortality and the cost associated with this devastating disease.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Idiopathic Pulmonary Fibrosis
  • Drug: Cotrimoxazole
    24 weeks of treatment
  • Drug: Placebo
    Identical capsules to cotrimoxazole
    Other Name: Placebo with identical physical appearance
  • Experimental: Cotrimoxazole
    Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
    Intervention: Drug: Cotrimoxazole
  • Placebo Comparator: Placebo
    Identical capsules to cotrimoxazole
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
56
December 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient, regardless of gender, aged 18 to 80 years.
  • Well-established diagnostic criteria of the Idiopathic Pulmonary Fibrosis (IPF) as ATA/ERS/JRS/ALAT 2011.
  • Ability to obtain a sample of sputum or oropharyngeal washing.
  • Forced Vital Capacity (FVC) above 50% from the theoretical value expected.
  • Patient compliance or legal guardian to participate in this study by signing the informed consent.

Exclusion Criteria:

  • Allergy / hypersensitivity or known gastrointestinal intolerance to cotrimoxazole.
  • Use of immunosuppressants or corticosteroids in the previous 90 days at baseline.
  • Exacerbation of IPF and / or pneumonia in the 90 days prior to baseline.
  • Presence of autoimmune diseases or asthma.
  • Patients with other significant diseases other than IPF. It is considered significant disease any disease or condition that, in the investigator's opinion, may jeopardize the patient's health participating in the study or influence the results of the study or the patient's ability to participate in the study.
  • Pregnant or lactating or of childbearing potential not using medically approved contraceptive methods at least three months before or during trial.
  • Participation in another trial with an investigational drug within 30 days or six half-lives (the larger of the two) above the baseline.
Both
18 Years to 80 Years
No
Contact: Francisco J. Medrano Ortega, PhD medrano@cica.es
Contact: Fernando Pérez Martínez, PhD 955013414 fernando.perez.exts@juntadeandalucia.es
Spain
 
NCT01777737
TriSulfa-FPI-1
No
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Junta de Andalucia
Not Provided
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP